Business Description
BriaCell Therapeutics Corp. is a Canadian cancer treatment company working to develop new ways to use the immune system to fight tumors, with a particular focus on advanced breast cancer. Its main treatment, Bria-IMT, is currently being tested in Phase 3 clinical trials, while a related therapy called Bria-OTS is being developed as a ready-made, personalized option for patients with several types of cancer, including prostate cancer. The company also holds a licensing agreement with the University of Maryland Baltimore County to advance a protein-based therapy that helps the immune system recognize and attack cancer cells. BriaCell works with the MSK Accelerator to speed up the development of its treatments across a range of cancer types.
